USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
Discovery of New Targeted Therapies Will Replace Conventional Therapies
28-Jan-2015
Market Research
MAC3-01-00-00-00
LS00105-GL-MR_16946
This study assesses marketed and in-research products and combination regimens for the lung cancer therapeutics market. Segmentation by drug class is provided, along with additional supporting information such as clinical trial timelines and results, historical and projected launch timelines, and epidemiology. The marketed and pipeline products are broadly segmented by their mechanism of action against cancer. Cost-effective treatments and targeted therapies are the key unmet needs of the market.
Executive Summary
Executive Summary (continued)
Executive Summary (continued)
Methodology and Scope
Market Overview—Segmentation
Market Overview—Segmentation (continued)
Market Overview—Segmentation (continued)
Recent Market Developments
Companies to Watch
Key Merger, Acquisition, and Partnership Assessment
Game-changing Strategies
Epidemiology
Epidemiology (continued)
Epidemiology (continued)
Competitive Landscape—Marketed and Pipeline Drugs in Pre-registration and Phase 3
Competitive Landscape—Pipeline Drugs in Phase 1 and Phase 2
Timeline of Product Launches/Approval
Timeline of Patent Expiries
Competitive Landscape—Pivotal Clinical Trials
Competitive Landscape—Pivotal Clinical Trials (continued)
Marketed Products Synopsis
Marketed Products Synopsis (continued)
Marketed Products Synopsis (continued)
Marketed Products Synopsis (continued)
Pipeline Synopsis
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Pipeline Synopsis (continued)
Product Dashboard: Tarceva® (Erlotinib)—Roche Group
Product Dashboard: Gilotrif® (Afatinib)—Boehringer Ingelheim
Product Dashboard: Avastin® (Bevacizumab)—Genentech Inc. (Roche Group)
Product Dashboard: Alimta® (Pemetrexed)—Eli Lilly and Company
Product Dashboard: XALKORI® (Crizotinib)—Pfizer Inc.
Product Dashboard: AP26113—Ariad Pharmaceuticals, Inc.
Product Dashboard: Necitumumab—Eli Lilly and Company
Product Dashboard: Nivolumab—Bristol-Myers Squibb Company and Ono Pharmaceutical
Conclusions
Legal Disclaimer
About Lung Cancer
About Lung Cancer (continued)
The Frost & Sullivan Story
Value Proposition: Future of Your Company & Career
Global Perspective
Industry Convergence
360º Research Perspective
Implementation Excellence
Our Blue Ocean Strategy
Speak directly with our analytics experts for tailored recommendations.
Recent related Life Sciences research
13 Jan 2025 | Global | Market Outlook
Top 6 Growth Opportunities for the Digital Health Industry, 2025
Driven by digital advancements, the healthcare industry is transforming rapidly. Current trends and challenges create constant change, and industry stakeholders must adapt to remain attractive, competitive, and unique as robust organizations. Each year, competitors must gain a fresh, comprehensive v...
17 Dec 2024 | Global | Market Research
Cybersecurity in Healthcare, United States, 2024
Healthcare is the industry most affected by cyberattacks, which have targets like hospitals, healthcare organizations, patient databases, and connected devices. These attacks not only destabilize healthcare systems but also threaten care delivery and patient safety. The global healthcare infrastruct...
12 Dec 2024 | Global | Market Outlook
Top 6 Growth Opportunities for Clinical Diagnostics, Global, 2025
Accounting for 2%-3% of total healthcare expenditure and influencing 70% of clinical decision-making, diagnostics is the silent champion supporting all stages of precision health, including risk stratification, screening, early diagnosis, prognosis, monitoring, and relapse. The discovery and trans...
05 Dec 2024 | Global | Frost Radar
Frost Radar™: Enterprise Conversational AI in Healthcare, 2024
This Frost Radar™ benchmarks the companies and their solutions that allow healthcare payers and providers to create next-generation virtual assistants. Conversational AI is primarily used to streamline patient and provider processes and interactions across the care continuum—the pre-care, at-care, a...
27 Nov 2024 | Global | Market Research
Generative AI in Payer and Provider IT Transformation, Global, 2024-2029
The healthcare payer and provider industry is gradually adopting generative artificial intelligence (Gen AI) solutions across its value chain. Almost all organizations have shown an intent to implement Gen AI-based solutions in their products or processes, with a few already embarking on this journe...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
| Deliverable Type | Market Research |
|---|---|
| No Index | No |
| Podcast | No |
| Author | Sumedha Pareek |
| WIP Number | MAC3-01-00-00-00 |
| Is Prebook | No |
A Product and Pipeline Analysis of the Lung Cancer Therapeutics Market
$3,950.00
Special Price $2,962.50 save 25 %